CD24 and neoplasm: Wright and colleagues have shown cellular heterogenicity of CSCs by using a mouse knockout model of BRCA1. A subpopulation from one tumour with stem cell properties was CD44+/ CD24-, whereas cells that have been derived from another tumour contained a CSC population with CD133 expression.